The impact of cystic fibrosis on the immunologic profile of pediatric patients

Jornal de Pediatria

Volumn 89, Issue 1, 2013, Pages 40-47

  Bernardi, Daniela M ^a   Ribeiro, Antonio F ^b   Mazzola, Tais N ^b   Vilela, Maria M S ^b   Sgarbieri, Valdemiro C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Medical School   (Brazil)

Author keywords

Cystic fibrosis; Cytokines; Glutathione; Immunoglobulins; Reactive oxygen species

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; GLUTATHIONE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PHYTOHEMAGGLUTININ; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNITY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; SALIVA LEVEL; SCHOOL CHILD;

EID: 84875264276     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jped.2013.02.007     Document Type: Article

References (36)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373: 1891-904.
2. Cheung JC, Kim Chiaw P, Pasyk S, Bear CE. Molecular basis for the ATPase activity of CFTR. Arch Biochem Biophys. 2008;476:95-100.
3. Rottner M, Freyssinet JM, Martínez MC. Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir Res. 2009;10:23.
4. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med. 2012;18:509-19.
5. Beutler E, editor. Red Cell Metabolism. New York: Churchill Livingstone; 1986. p. 126.
6. Emmendörffer A, Hecht M, Lohmann-Matthes ML, Roesler J. A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123. J Immunol Methods. 1990;131: 269-75.
7. Richardson MP, Ayliffe MJ, Helbert M, Davies EG. A simple flow cytometry assay using dihydrorhodamine for the measurement of the neutrophil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test. J Immunol Methods. 1998;219:187-93.
8. Gaines H, Andersson L, Biberfeld G. A new method for measuring lymphoproliferation at the single-cell level in whole blood cultures by flow cytometry. J Immunol Methods. 1996;195:63-72.
9. Boncoeur E, Criq VS, Bonvin E, Roque T, Henrion-Caude A, Gruenert DC, et al. Oxidative stress induces extracellular signalregulated kinase 1/2 mitogen-activated protein kinase in cystic fibrosis lung epithelial cells: potential mechanism for excessive IL-8 expression. Int J Biochem Cell Biol. 2008;40:432-46.
10. Mangione S, Patel DD, Levin BR, Fiel SB. Erythrocytic glutathione in cystic fibrosis. A possible marker of pulmonary dysfunction. Chest. 1994;105:1470-3.
11. Lands LC, Grey V, Smountas AA, Kramer VG, McKenna D. Lymphocyte glutathione levels in children with cystic fibrosis. Chest. 1999;116:201-5.
12. Gao L, Kim KJ, Yankaskas JR, Forman HJ. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol. 1999;277:L113-8.
13. Norman D, Elborn JS, Cordon SM, Rayner RJ, Wiseman MS, Hiller EJ, et al. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax. 1991;46:91-5.
14. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995;20:63-70.
15. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995;152:2111-8.
16. Osika E, Cavaillon JM, Chadelat K, Boule M, Fitting C, Tournier G, et al. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J. 1999; 14:339-46.
17. Karpati F, Hjelte FL, Wretlind B. TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment. Scand J Infect Dis. 2000;32:75-9.
18. Pukhalsky AL, Kapranov NI, Kalashnikova EA, Shmarina GV, Shabalova LA, Kokarovtseva SN, et al. Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection. Mediators Inflamm. 1999;8:159-67.
19. Moser C, Kjaergaard S, Pressler T, Kharazmi A, Koch C, Høiby N. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS. 2000;108:329-35.
20. Wojnarowski C, Frischer T, Hofbauer E, Grabner C, Mosgoeller W, Eichler I, et al. Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation. Eur Respir J. 1999;14:1136-44.
21. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis. 1997;175:638-47.
22. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med. 1998;157:1764-9.
23. Nichols D, Chmiel J, Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter-and intracellular signaling. Clin Rev Allergy Immunol. 2008;34:146-62.
24. Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, et al. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol. 1996;106:374-88.
25. Rosensweig JN, Omori M, Page K, Potter CJ, Perlman EJ, Thorgeirsson SS, et al. Transforming growth factor-beta1 in plasma and liver of children with liver disease. Pediatr Res. 1998;44:402-9.
26. South MA, Warwick WJ, Wolheim FA, Good RA. The IgA system. 3. IgA levels in the serum and saliva of pediatric patients-evidence for a local immunological system. J Pediatr. 1967;71: 645-53.
27. Gugler E, Pallavicini JC, Swedlow H, Zipkin I, Agnese PA. Immunological studies of submaxillary saliva from patients with cystic fibrosis and from normal children. J Pediatr. 1968; 73:548-59.
28. Hodson ME, Morris L, Batten JC. Serum immunoglobulins and immunoglobulin G subclasses in cystic fibrosis related to the clinical state of the patient. Eur Respir J. 1988;1:701-5.
29. Matthews WJ Jr, Williams M, Oliphint B, Geha R, Colten HR. Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J Med. 1980;302:245-9.
30. Wheeler WB, Williams M, Matthews WJ Jr, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr. 1984;104:695-9.
31. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology. 2007;153:917-23.
32. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416.
33. Kremer TM, Zwerdling RG, Michelson PH, O'Sullivan P. Intensive care management of the patient with cystic fibrosis. J Intensive Care Med. 2008;23:159-77.
34. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-22.
35. Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol. 2012;20: 419-28.
36. Pier GB. The challenges and promises of new therapies for cystic fibrosis. J Exp Med. 2012;209:1235-9.